Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Royalty Pharma plc. A complete text table follows the diagram.
A portfolio of rights across rare disease, oncology, respiratory, immunology, and neuroscience converted other companies' drug sales into $925M of quarterly receipts.
Swipe to explore
Cystic fibrosis, Trelegy, Tremfya, Tysabri, Promacta, and Other products remain reported lines. Rare disease and oncology combine disclosed product receipts arithmetically by the filing's therapeutic-area labels.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Cystic fibrosis franchise | 1 | $253M | Vertex; 29% of royalty receipts |
| Oncology portfolio | 1 | $189M | Six marketed medicines |
| Other rare disease | 1 | $99.6M | Evrysdi, Spinraza and Amvuttra |
| Trelegy | 1 | $97.7M | GSK respiratory franchise |
| Tremfya | 1 | $64M | Up 80% year over year |
| Tysabri | 1 | $59.3M | Biogen neuroscience royalty |
| Promacta | 1 | $17.2M | Novartis hematology royalty |
| Other products | 1 | $108M | Diversified long tail |
| Royalty receipts | 2 | $887M | Up 12.5% year over year |
| Milestones and contracts | 2 | $38.2M | Non-royalty portfolio receipts |
| Portfolio receipts | 3 | $925M | Cash engine before operating costs |
| From | To | Value |
|---|---|---|
| Cystic fibrosis franchise | Royalty receipts | $253M |
| Oncology portfolio | Royalty receipts | $189M |
| Other rare disease | Royalty receipts | $99.6M |
| Trelegy | Royalty receipts | $97.7M |
| Tremfya | Royalty receipts | $64M |
| Tysabri | Royalty receipts | $59.3M |
| Promacta | Royalty receipts | $17.2M |
| Other products | Royalty receipts | $108M |
| Royalty receipts | Portfolio receipts | $887M |
| Milestones and contracts | Portfolio receipts | $38.2M |